In Kazakhstan, eight pharmaceutical production facilities will be built or expanded. The new enterprises are set to produce around 500 types of medicines for the treatment of cancer, cardiovascular and infectious diseases, as well as diabetes. The facilities will be located in Almaty, Shymkent, the Almaty region, and the Karagandy region. Over the past three years, the country’s pharmaceutical production has grown by 37%, reaching 191 billion tenge. Over 200 pharmaceutical and medical product manufacturers operate in Kazakhstan, 43 of which produce medicines. Also, AstraZeneca, Pfizer, and Roche have begun localizing production in the country. The developments are expected to reduce Kazakhstan’s import dependence.
«As of August 2026, the share of domestically produced goods
in physical terms reached 40.3%. At the same time, the long-term procurement
mechanism continues to develop. As of the beginning of 2026, 83 contracts were
in place with 31 domestic manufacturers for the supply of 2,022 product items,» said Timur Muratov, Kazakh Vice Minister of Health.
Related Articles
